Skip to Main Content

IBM is modifying its Watson software that recommends cancer treatments so that it reflects geographic differences in how patients are treated around the world, according to a recording of a staff meeting reviewed by STAT.

That represents a major shift for IBM on a venture that the company has aggressively promoted as having the potential to revolutionize medicine. It has long marketed Watson for Oncology as being based on the expertise of doctors at the prestigious New York cancer center who trained it. But some physicians at foreign hospitals that use or have considered buying the software have complained about irrelevant or inaccurate treatment recommendations and expressed dissatisfaction with its American bias.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.